CUE Stock Summary and Trading Ideas (Cue Biopharma | NASDAQ:CUE)

Cue Biopharma Inc is a clinical-stage therapeutics company focused on advancing a robust portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its product pipeline includes CUE-221, an anti-IgE antibody candidate being developed for allergic diseases. The company has also developed the Immuno-STAT platform for targeting disease-related T cells and is developing CUE-401, an IL-2 and TGF-B therapeutic candidate for autoimmune diseases.

Cue Biopharma trades on the NASDAQ stock market under the symbol CUE.

As of November 5, 2026, CUE stock price declined to $18.01 with 140,965 million shares trading.

CUE has a beta of 4.84, meaning it tends to be more sensitive to market movements. CUE has a correlation of 0.10 to the broad based SPY ETF.

CUE has a market cap of $130.83 million. This is considered a Micro Cap stock.

Last quarter Cue Biopharma reported $8 million in Revenue and -$24.14 earnings per share. This beat revenue expectation by $5 million and missed earnings estimates by -$22.76.

In the last 3 years, CUE traded as high as $97.47 and as low as $4.97.

The top ETF exchange traded funds that CUE belongs to (by Net Assets): VTI, VXF, IWC, AVSC, AVTM.

CUE has underperformed the market in the last year with a return of -16.8%, while the SPY ETF gained +9.7%. In the last 3 month period, CUE fell short of the market, returning -32.3%, while SPY returned -4.7%. However, in the most recent 2 weeks CUE has outperformed the stock market by returning -5.0%, while SPY returned -5.2%.

CUE support price is $17.88 and resistance is $21.80 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CUE shares will trade within this expected range on the day.